Skip to Content

Clopidogrel Acino Pharma GmbH

Active Substance: clopidogrel
Common Name: clopidogrel
ATC Code: B01AC04
Marketing Authorisation Holder: Acino Pharma GmbH
Active Substance: clopidogrel
Status: Withdrawn
Authorisation Date: 2009-09-21
Therapeutic Area: Peripheral Vascular Diseases Stroke Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

  • patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

For further information please refer to section 5.1.

The marketing authorisation for Clopidogrel Acino Pharma GmbH has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide